Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a report issued on Friday,Benzinga reports. The firm currently has a $20.00 price target on the stock.

Poseida Therapeutics Stock Performance

Shares of NASDAQ:PSTX opened at $3.71 on Friday. The firm has a market capitalization of $360.35 million, a PE ratio of -5.89 and a beta of 0.54. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The business has a 50-day moving average of $2.77 and a two-hundred day moving average of $2.90. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $4.27.

Institutional Investors Weigh In On Poseida Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its stake in Poseida Therapeutics by 14.2% during the second quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after acquiring an additional 3,552 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock worth $283,000 after buying an additional 3,875 shares during the period. American Century Companies Inc. boosted its position in shares of Poseida Therapeutics by 5.9% in the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after buying an additional 5,023 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Poseida Therapeutics by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after buying an additional 9,672 shares during the period. Finally, Bayesian Capital Management LP purchased a new stake in shares of Poseida Therapeutics in the first quarter worth about $33,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.